Literature DB >> 29548054

Neurofibromatosis and Schwannomatosis.

Scott R Plotkin1, Antje Wick2.   

Abstract

Neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis are a group of related classically inherited but often times sporadic tumor suppressor syndromes. Neuro-oncologists should recognize these syndromes, initiate necessary tests in patients with a clinical suspicion, and support genetic counseling of patients and families. In this review, clinical presentation, diagnostic criteria, day-to-day management including supportive care as well as updates on genetics, and experimental treatment strategies are discussed. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2018        PMID: 29548054     DOI: 10.1055/s-0038-1627471

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  16 in total

Review 1.  Current status and recommendations for imaging in neurofibromatosis type 1, neurofibromatosis type 2, and schwannomatosis.

Authors:  Shivani Ahlawat; Jaishri O Blakeley; Shannon Langmead; Allan J Belzberg; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2019-08-08       Impact factor: 2.199

2.  A Linear Variant of Segmental Schwannomatosis Localized to the Upper Extremity.

Authors:  Ashkaun Shaterian; Tuna Ozyurekoglu
Journal:  J Hand Microsurg       Date:  2020-09-22

3.  Depression explains the association between pain intensity and pain interference among adults with neurofibromatosis.

Authors:  James D Doorley; Jonathan Greenberg; Jafar Bakhshaie; Nathan S Fishbein; Ana-Maria Vranceanu
Journal:  J Neurooncol       Date:  2021-08-19       Impact factor: 4.506

4.  Targetable ERBB2 mutations identified in neurofibroma/schwannoma hybrid nerve sheath tumors.

Authors:  Michael W Ronellenfitsch; Patrick N Harter; Martina Kirchner; Christoph Heining; Barbara Hutter; Laura Gieldon; Jens Schittenhelm; Martin U Schuhmann; Marcos Tatagiba; Gerhard Marquardt; Marlies Wagner; Volker Endris; Christian H Brandts; Victor-Felix Mautner; Evelin Schröck; Wilko Weichert; Benedikt Brors; Andreas von Deimling; Michel Mittelbronn; Joachim P Steinbach; David E Reuss; Hanno Glimm; Albrecht Stenzinger; Stefan Fröhling
Journal:  J Clin Invest       Date:  2020-05-01       Impact factor: 14.808

5.  Difference in the hypoxic immunosuppressive microenvironment of patients with neurofibromatosis type 2 schwannomas and sporadic schwannomas.

Authors:  Ryota Tamura; Yukina Morimoto; Mizuto Sato; Yuki Kuranari; Yumiko Oishi; Kenzo Kosugi; Kazunari Yoshida; Masahiro Toda
Journal:  J Neurooncol       Date:  2020-01-03       Impact factor: 4.130

Review 6.  Neurocutaneous syndromes in art and antiquities.

Authors:  Martino Ruggieri; Amalia Egle Gentile; Vincenza Ferrara; Massimo Papi; Andrea D Praticò; Albert Mudry; Domenica Taruscio; Giuseppe Micali; Agata Polizzi
Journal:  Am J Med Genet C Semin Med Genet       Date:  2021-05-20       Impact factor: 3.908

7.  Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study.

Authors:  Akram Sanagoo; Leila Jouybari; Fatemeh Koohi; Fatemeh Sayehmiri
Journal:  BMC Neurol       Date:  2019-06-12       Impact factor: 2.474

8.  A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2.

Authors:  Ryota Tamura; Masato Fujioka; Yukina Morimoto; Kentaro Ohara; Kenzo Kosugi; Yumiko Oishi; Mizuto Sato; Ryo Ueda; Hirokazu Fujiwara; Tetsuro Hikichi; Shinobu Noji; Naoki Oishi; Kaoru Ogawa; Yutaka Kawakami; Takayuki Ohira; Kazunari Yoshida; Masahiro Toda
Journal:  Nat Commun       Date:  2019-12-17       Impact factor: 14.919

9.  Mesenchymal Neoplasms of Salivary Glands: A Clinicopathologic Study of 68 Cases.

Authors:  Jaylou M Velez Torres; Ernesto Martinez Duarte; Julio A Diaz-Perez; Jason Leibowitz; Donald T Weed; Giovanna Thomas; Zoukaa Sargi; Francisco J Civantos; David J Arnold; Carmen Gomez-Fernandez; Elizabeth A Montgomery; Andrew E Rosenberg
Journal:  Head Neck Pathol       Date:  2021-07-12

10.  Schwannoma development is mediated by Hippo pathway dysregulation and modified by RAS/MAPK signaling.

Authors:  Zhiguo Chen; Stephen Li; Juan Mo; Eric Hawley; Yong Wang; Yongzheng He; Jean-Philippe Brosseau; Tracey Shipman; D Wade Clapp; Thomas J Carroll; Lu Q Le
Journal:  JCI Insight       Date:  2020-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.